Glenn S. Van Aller
GlaxoSmithKline (United States)(US)
Publications by Year
Research Areas
Epigenetics and DNA Methylation, Cancer-related gene regulation, Peptidase Inhibition and Analysis, PI3K/AKT/mTOR signaling in cancer, RNA modifications and cancer
Most-Cited Works
- → EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations(2012)1,779 cited
- → EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation(2013)832 cited
- → A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC(2015)503 cited
- → SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer(2014)406 cited
- → Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2(2012)375 cited
- → Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin(2010)368 cited
- → Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation(2012)174 cited
- → Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor(2011)169 cited
- → Identification, Substrate Specificity, and Inhibition of theStreptococcus pneumoniae β-Ketoacyl-Acyl Carrier Protein Synthase III (FabH)(2001)98 cited
- → First X-ray Cocrystal Structure of a Bacterial FabH Condensing Enzyme and a Small Molecule Inhibitor Achieved Using Rational Design and Homology Modeling(2002)72 cited